{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:52:49Z","timestamp":1773388369568,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12185-025-03986-2","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:45:20Z","timestamp":1745819120000},"page":"381-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro evaluation of global coagulation potential of emicizumab and warfarin using rotational thromboelastometry"],"prefix":"10.1007","volume":"122","author":[{"given":"Takahiro","family":"Kajimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"1","key":"3986_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/hae.12074","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Treatment guidelines working group on behalf of the world federation of hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.","journal-title":"Haemophilia"},{"issue":"3","key":"3986_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1055\/s-0040-1718410","volume":"121","author":"B Guillet","year":"2021","unstructured":"Guillet B, Cayla G, Lebreton A, Trillot N, Wibaut B, Falaise C, et al. Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: results from the french registry. Thromb Haemost. 2021;121(3):287\u201396.","journal-title":"Thromb Haemost"},{"issue":"5","key":"3986_CR3","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1111\/hae.13069","volume":"22","author":"K Berger","year":"2016","unstructured":"Berger K, Schopohl D, Lowe G, Holme PA, Tait RC, Combescure C, et al. How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population. Haemophilia. 2016;22(5):e406\u201316.","journal-title":"Haemophilia"},{"issue":"11","key":"3986_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/bloodadvances.2018018226","volume":"2","author":"SL Sood","year":"2018","unstructured":"Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, et al. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018;2(11):1325\u201333.","journal-title":"Blood Adv"},{"issue":"5","key":"3986_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/hae.12445","volume":"20","author":"RE Schutgens","year":"2014","unstructured":"Schutgens RE, Klamroth R, Pabinger I, Malerba M, Dolan G, ADVANCE working group. Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe. Haemophilia. 2014;20(5):682\u20136.","journal-title":"Haemophilia"},{"issue":"3","key":"3986_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jth.12127","volume":"11","author":"JP Galanaud","year":"2013","unstructured":"Galanaud JP, Laroche JP, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost. 2013;11(3):402\u201311.","journal-title":"J Thromb Haemost"},{"issue":"22","key":"3986_CR7","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.3390\/jcm10225268","volume":"10","author":"C Bonanad","year":"2021","unstructured":"Bonanad C, Garc\u00eda-Blas S, Torres Llergo J, Fern\u00e1ndez-Olmo R, D\u00edez-Villanueva P, Ariza-Sol\u00e9 A, et al. Direct oral anticoagulants versus warfarin in octogenarians with nonvalvular atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2021;10(22):5268.","journal-title":"J Clin Med"},{"key":"3986_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2024.07.011","author":"CA Mack","year":"2024","unstructured":"Mack CA, Lau C, Girardi LN. There is still no alternative to warfarin for mechanical valves: it remains the most effective anticoagulant. J Thorac Cardiovasc Surg. 2024. https:\/\/doi.org\/10.1016\/j.jtcvs.2024.07.011.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"14","key":"3986_CR9","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.3390\/ijerph17144993","volume":"17","author":"G Lassandro","year":"2020","unstructured":"Lassandro G, Palmieri VV, Palladino V, Amoruso A, Faienza MF, Giordano P. Venous thromboembolism in children: from diagnosis to management. Int J Environ Res Public Health. 2020;17(14):4993.","journal-title":"Int J Environ Res Public Health"},{"key":"3986_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/TCRM.S218622","volume":"16","author":"A Bosch","year":"2020","unstructured":"Bosch A, Albisetti M. Management of venous thromboembolism in children: current recommendations and therapeutic options. Ther Clin Risk Manag. 2020;16:673\u20139.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"3986_CR11","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.2215\/CJN.00770208","volume":"3","author":"J Danziger","year":"2008","unstructured":"Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008;3(5):1504\u201310.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3986_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/tpj.2011.4","volume":"12","author":"A Pavani","year":"2012","unstructured":"Pavani A, Naushad SM, Rupasree Y, Kumar TR, Malempati AR, Pinjala RK, et al. Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J. 2012;12(4):306\u201311.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"3986_CR13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11739-023-03331-7","volume":"18","author":"A Tripodi","year":"2023","unstructured":"Tripodi A, Mannucci PM, Peyvandi F. Hemophilia patients: are they naturally anticoagulated? Intern Emerg Med. 2023;18(5):1251\u20134.","journal-title":"Intern Emerg Med"},{"issue":"5","key":"3986_CR14","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/jth.13674","volume":"15","author":"MLY de Koning","year":"2017","unstructured":"de Koning MLY, Fischer K, de Laat B, Huisman A, Ninivaggi M, Schutgens REG. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. J Thromb Haemost. 2017;15(5):868\u201375.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"3986_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/hae.12109","volume":"19","author":"A Tuinenburg","year":"2013","unstructured":"Tuinenburg A, Damen SA, Ypma PF, Mauser-Bunschoten EP, Voskuil M, Schutgens RE. Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline. Haemophilia. 2013;19(3):370\u20137.","journal-title":"Haemophilia"},{"issue":"5","key":"3986_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/hae.12652","volume":"21","author":"PF Fogarty","year":"2015","unstructured":"Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Emerging Hemophilia Panel (GEHEP), et al. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015;21(5):589\u201397.","journal-title":"Haemophilia"},{"issue":"10","key":"3986_CR17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570\u20134.","journal-title":"Nat Med"},{"issue":"21","key":"3986_CR18","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"3986_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jth.12474","volume":"12","author":"A Muto","year":"2014","unstructured":"Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, et al. Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206\u201313.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3986_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","volume":"115","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Mizumachi K, Shimonishi N, Furukawa S, Yada K, Ogiwara K, et al. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients. Int J Hematol. 2022;115(4):489\u201398.","journal-title":"Int J Hematol"},{"issue":"7","key":"3986_CR21","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/TH17-01-0030","volume":"117","author":"T Kitazawa","year":"2017","unstructured":"Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348\u201357.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3986_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/hae.14911","volume":"30","author":"K Mizumachi","year":"2024","unstructured":"Mizumachi K, Nakajima Y, Shimonishi N, Furukawa S, Ogiwara K, Takeyama M, et al. Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity. Haemophilia. 2024;30(1):140\u201350.","journal-title":"Haemophilia"},{"issue":"4","key":"3986_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","volume":"110","author":"K Yada","year":"2019","unstructured":"Yada K, Nogami K, Ogiwara K, Shida Y, Furukawa S, Yaoi H, et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol. 2019;110(4):419\u201330.","journal-title":"Int J Hematol"},{"issue":"7","key":"3986_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/jth.12987","volume":"13","author":"S Furukawa","year":"2015","unstructured":"Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015;13(7):1279\u201384.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 4","key":"3986_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/hae.14524","volume":"28","author":"J Mahlangu","year":"2022","unstructured":"Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022;28(Suppl 4):103\u201310.","journal-title":"Haemophilia"},{"issue":"20","key":"3986_CR26","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-07-727032","volume":"128","author":"RE Schutgens","year":"2016","unstructured":"Schutgens RE, van der Heijden JF, Mauser-Bunschoten EP, Mannucci PM. New concepts for anticoagulant therapy in persons with hemophilia. Blood. 2016;128(20):2471\u20134.","journal-title":"Blood"},{"issue":"7","key":"3986_CR27","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3324\/haematol.2022.282407","volume":"108","author":"M Franchini","year":"2023","unstructured":"Franchini M, Focosi D, Mannucci PM. How we manage cardiovascular disease in patients with hemophilia. Haematologica. 2023;108(7):1748\u201357.","journal-title":"Haematologica"},{"issue":"4","key":"3986_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/hae.15062","volume":"30","author":"Y Xu","year":"2024","unstructured":"Xu Y, Wang Y, Wu R, Zheng C, Zhang L, Xu W, et al. Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicentre real-world study in China. Haemophilia. 2024;30(4):959\u201369.","journal-title":"Haemophilia"},{"issue":"1","key":"3986_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hae.14707","volume":"29","author":"A Chuansumrit","year":"2023","unstructured":"Chuansumrit A, Sirachainan N, Jaovisidha S, Jiravichitchai T, Kadegasem P, Kempka K, et al. Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: a case series report. Haemophilia. 2023;29(1):382\u20135.","journal-title":"Haemophilia"},{"issue":"2","key":"3986_CR30","first-page":"218","volume":"124","author":"JH Yu","year":"2011","unstructured":"Yu JH, Guo HW, Zhang G, Wu SM, Song GM, Sun WY. Valve replacement in pediatric patients: a single center experience. Chin Med J (Engl). 2011;124(2):218\u201322.","journal-title":"Chin Med J (Engl)"},{"key":"3986_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpeds.2017.04.051","volume":"189","author":"AL Baker","year":"2017","unstructured":"Baker AL, Vanderpluym C, Gauvreau KA, Fulton DR, de Ferranti SD, Friedman KG, et al. Safety and efficacy of warfarin therapy in kawasaki disease. J Pediatr. 2017;189:61\u20135.","journal-title":"J Pediatr"},{"issue":"4","key":"3986_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacc.2022.10.037","volume":"81","author":"J Van den Eynde","year":"2023","unstructured":"Van den Eynde J, Possner M, Alahdab F, Veldtman G, Goldstein BH, Rathod RH, et al. Thromboprophylaxis in patients with fontan circulation. J Am Coll Cardiol. 2023;81(4):374\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3986_CR33","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","volume":"94","author":"W Streif","year":"1999","unstructured":"Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94(9):3007\u201314.","journal-title":"Blood"},{"issue":"5","key":"3986_CR34","first-page":"e72","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143(5):e72\u2013227.","journal-title":"Circulation"},{"issue":"13","key":"3986_CR35","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden AB. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559.","journal-title":"J Am Heart Assoc"},{"key":"3986_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2024.03.031","volume":"237","author":"C Dix","year":"2024","unstructured":"Dix C, McFadyen JD, Tran HA. Exploring the effects of factor Xa inhibitors on thrombin generation in people with haemophilia. Thromb Res. 2024;237:148\u201353.","journal-title":"Thromb Res"},{"issue":"7","key":"3986_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102576","volume":"8","author":"S Lamoine","year":"2024","unstructured":"Lamoine S, Jury V, Fourneyron V, Douxfils J, Teissandier D, Talon L, et al. Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII. Res Pract Thromb Haemost. 2024;8(7): 102576.","journal-title":"Res Pract Thromb Haemost"},{"key":"3986_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.thromres.2024.03.023","volume":"237","author":"K Yada","year":"2024","unstructured":"Yada K, Fujitate N, Ogiwara K, Soeda T, Kitazawa T, Nogami K. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro. Thromb Res. 2024;237:37\u201345.","journal-title":"Thromb Res"},{"issue":"Pt B","key":"3986_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijsu.2015.09.036","volume":"33","author":"K Abdelfattah","year":"2016","unstructured":"Abdelfattah K, Cripps MW. Thromboelastography and rotational thromboelastometry use in trauma. Int J Surg. 2016;33(Pt B):196\u2013201.","journal-title":"Int J Surg"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03986-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:18:56Z","timestamp":1757161136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3986"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03986-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TK and NT have no disclosure of conflict of interest. YN has received grant from the Takeda Pharmaceutical Company. KN has received grants, personal fees, non-financial support from Chugai Pharmaceutical Co., Ltd., personal fees from F. Hoffmann-La Roche Ltd., grants, personal fees and non-financial support from Sysmex Co., grants and personal fees from Takeda Pharmaceutical Co., grants and personal fees from Sanofi S.A, personal fees from CSL Behring Co., grants and personal fees from KM Biologics Co., grants and personal fees from Novo Nordisk A\/S, grants and personal fees from Bayer AG, grants and personal fees from Bioverativ Inc, and grants and personal fees from Shire Plc, and is an inventor of the patents relating to emicizumab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}